Vita 34: Was passion in the US?

On September 27, 2023, Vita 34 AG started the formation of Tochtergesellschaften FamiCordTx SA (“FamiCordTx”) and Polski Bank Komórek Macierzystych sp. z oo (“PBKM”) eine Klage gegen un American-American Biotechnologieunternehmen (“Lizenzgeber”) eingereicht, da der Lizenzgeber nicht in der Lage war, de Lizenzvereinbarung einzuhalten, in Rahmen derer FamiCordTx und PBKM eine Exclusief genehmigung voor de Nutzung der CAR – T-Technology (die “CAR-T-Lizenz”) is available. Because the Lizenz geber does not have the CAR-T-Lizenz in the context of the hereditary project, there is talk of connteiling. On the basis of this, Lizenz has investigated FamiCordTx, a Krebs immunotherapy for treatment and marketing.

The Zivilklage was finalized at a Bezirksgericht der Vereinigten Staaten on September 27, 2023. In de Klage we were also asked to comply with the terms of reference of the Vereinbarung durch de Lizenzgeber current authority. Trotz der Einreichung der Klage setzten die beteiligten Parteien de Verhandlungen in gutem Glauben fort, um diesen Streit beizulegen.

It has become part of your enterprise that one of the best Lizenz-vertrags and a new Know-how-Lizenzvertrag Zwischen FamiCordTx and PBKM are on one of the one and the Lizenzgeber on the other pages, who have the appropriate rights.

The new Know-how-Lizenz-delay is in the context of a universal technology and know-how, which by Lizenzgeber a FamiCordTx and PBKM-overtragen were. The know-how that the CAR-T technology offers, is specialized in adapting projects, and sees new market conditions by FamiCordTx and PBKM in the fall of a commercial use or a sale of a milestone payment.